Gudrun Schleiermacher

List of Publications by Year
in descending order

146 papers	10,615 citations	47006 47 h-index	36028 97 g-index
155 all docs	155 docs citations	155 times ranked	11892 citing authors

#	Article	IF	Citations
1	The feasibility of using liquid biopsies as a complementary assay for copy number aberration profiling in routinely collected paediatric cancer patient samples. European Journal of Cancer, 2022, 160, 12-23.	2.8	16
2	Intraâ€•and extraâ€cranial <scp>BCORâ€‹ITD</scp> tumours are separate entities within the <scp>BCOR</scp>â€rearranged family. Journal of Pathology: Clinical Research, 2022, 8, 217-232.	3.0	10
3	Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	26
4	INSP-15. ITCC-P4: A sustainable platform of molecularly well-characterized PDX models of pediatric cancers for high throughputin vivo testing. Neuro-Oncology, 2022, 24, i189-i189.	1.2	0
5	Clinical characteristics and outcomes of children with WAGR syndrome and Wilms tumor and/or nephroblastomatosis: The 30â€year SIOPâ€RTSG experience. Cancer, 2021, 127, 628-638.	4.1	30
6	Minimally invasive classification of paediatric solid tumours using reduced representation bisulphite sequencing of cell-free DNA: a proof-of-principle study. Epigenetics, 2021, 16, 196-208.	2.7	23
7	NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets. JCO Precision Oncology, 2021, 5, 450-454.	3.0	2
8	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. American Journal of Surgical Pathology, 2021, 45, 854-867.	3.7	12
9	A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma. Cancers, 2021, 13, 1807.	3.7	4
10	Multimodal analysis of cell-free DNA whole-genome sequencing for pediatric cancers with low mutational burden. Nature Communications, 2021, 12, 3230.	12.8	95
11	Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Journal of Clinical Oncology, 2021, 39, 3377-3390.	1.6	30
12	Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. Journal of Clinical Oncology, 2021, 39, 2552-2563.	1.6	42
13	Molecular diagnosis of retinoblastoma by circulating tumor DNA analysis. European Journal of Cancer, 2021, 154, 277-287.	2.8	7
14	Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies. European Journal of Cancer, 2021, 157, 198-213.	2.8	34
15	First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSÃ©-ESMART trial. European Journal of Cancer, 2021, 157, 268-277.	2.8	19
16	Highly Sensitive Detection Method of Retinoblastoma Genetic Predisposition and Biomarkers. Journal of Molecular Diagnostics, 2021, 23, 1714-1721.	2.8	12
17	The pitfalls and promise of liquid biopsies for diagnosing and treating solid tumors in children: a review. European Journal of Pediatrics, 2020, 179, 191-202.	2.7	55
18	Data Resource Profile: The French Childhood Cancer Observation Platform (CCOP). International Journal of Epidemiology, 2020, 49, 1434-1435k.	1.9	11

#	Article	IF	Citations
19	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	1.6	0
20	Age Dependency of the Prognostic Impact of Tumor Genomics in Localized Resectable MYCN-Nonamplified Neuroblastomas. Report From the SIOPEN Biology Group on the LNESG Trials and a COG Validation Group. Journal of Clinical Oncology, 2020, 38, 3685-3697.	1.6	9
21	IL10RA Modulates Crizotinib Sensitivity in NPM1-ALK-positive Anaplastic Large Cell Lymphoma. Blood, 2020, 136, 1657-1669.	1.4	22
22	Maternal and perinatal characteristics, congenital malformations and the risk of wilms tumor: the ESTELLE study. Cancer Causes and Control, 2020, 31, 491-501.	1.8	4
23	Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma. European Journal of Cancer, 2020, 136, 52-68.	2.8	42
24	From Wilms to kidney tumors: which ones require a biopsy?. Pediatric Radiology, 2020, 50, 1049-1051.	2.0	14
25	Infant cancers in France: Incidence and survival (2000â€“2014). Cancer Epidemiology, 2020, 65, 101697.	1.9	13
26	Environmental exposures related to parental habits in the perinatal period and the risk of Wilms' tumor in children. Cancer Epidemiology, 2020, 66, 101706.	1.9	8
27	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. Journal of Clinical Oncology, 2020, 38, 1906-1918.	1.6	41
28	Biology of Neuroblastoma. , 2020, , 17-28.		0
29	Prognostic impact of postoperative 123I-metaiodobenzylguanidine scintigraphy: added value of SPECT/CT and semiquantification of the uptake at the surgical site. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2020, 64, 131-138.	0.7	0
30	Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis. International Journal of Cancer, 2019, 144, 68-79.	5.1	37
31	Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours. Nature Reviews Cancer, 2019, 19, 420-438.	28.4	98
32	Metastatic neuroblastoma in a patient with ROHHAD: A new alert regarding the risk of aggressive malignancies in this rare condition. Pediatric Blood and Cancer, 2019, 66, e27906.	1.5	8
33	ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations. Oncotarget, 2019, 10, 4937-4950.	1.8	5
34	Exosomal microRNAs from Longitudinal Liquid Biopsies for the Prediction of Response to Induction Chemotherapy in High-Risk Neuroblastoma Patients: A Proof of Concept SIOPEN Study. Cancers, 2019, 11, 1476.	3.7	43
35	Parental smoking, maternal alcohol consumption during pregnancy and the risk of neuroblastoma in children. A pooled analysis of the ESCALE and ESTELLE French studies. International Journal of Cancer, 2019, 145, 2907-2916.	5.1	12
36	Reply to comment on: The diagnostic accuracy and clinical utility of pediatric renal tumor biopsy: Report of the UK experience in the SIOP UK WT2001 trial. Pediatric Blood and Cancer, 2019, 66, e27828.	1.5	2

#	Article	IF	Citations
37	Study of chromatin remodeling genes implicates SMARCA4 as a putative player in oncogenesis in neuroblastoma. International Journal of Cancer, 2019, 145, 2781-2791.	5.1	16
38	Indications and results of diagnostic biopsy in pediatric renal tumors: A retrospective analysis of 317 patients with critical review of SIOP guidelines. Pediatric Blood and Cancer, 2019, 66, e27641.	1.5	31
39	Efficacy of Lorlatinib in Primary Crizotinib-Resistant Adult Neuroblastoma Harboring ALK Y1278S Mutation. JCO Precision Oncology, 2019, 3, 1-5.	3.0	5
40	The challenge of defining â€œultraâ€highâ€riskâ€•neuroblastoma. Pediatric Blood and Cancer, 2019, 66, e27556.	1.5	43
41	Abstract CT081: Pediatric precision medicine program in recurrent tumors: Results of the first 500 patients included in the European MAPPYACTS molecular profiling trial. Cancer Research, 2019, 79, CT081-CT081.	0.9	3
42	Can pediatric and adolescent patients with recurrent tumors benefit from a precision medicine program? The European MAPPYACTS experience.. Journal of Clinical Oncology, 2019, 37, 10018-10018.	1.6	3
43	Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients. Journal of the National Cancer Institute, 2018, 110, 1084-1093.	6.3	73
44	Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience. Journal of Pediatric Hematology/Oncology, 2018, 40, 426-432.	0.6	11
45	Enrollment in earlyâ€phase clinical trials in pediatric oncology: The experience at Institut Curie. Pediatric Blood and Cancer, 2018, 65, e26916.	1.5	6
46	QuantumClone: clonal assessment of functional mutations in cancer based on a genotype-aware method for clonal reconstruction. Bioinformatics, 2018, 34, 1808-1816.	4.1	20
47	Relevance of a molecular tumour board (MTB) for patientsâ€™ enrolment in clinical trials: experience of the Institut Curie. ESMO Open, 2018, 3, e000339.	4.5	37
48	Whole-Exome Sequencing of Cell-Free DNA Reveals Temporo-spatial Heterogeneity and Identifies Treatment-Resistant Clones in Neuroblastoma. Clinical Cancer Research, 2018, 24, 939-949.	7.0	127
49	Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome. Journal of Pediatric Hematology/Oncology, 2018, 40, 93-98.	0.6	11
50	TBX2 is a neuroblastoma core regulatory circuitry component enhancing MYCN/FOXM1 reactivation of DREAM targets. Nature Communications, 2018, 9, 4866.	12.8	91
51	Neuroblastoma: Diagnosis and Treatment. , 2018, , 1-1.		0
52	Risk stratification of highâ€risk metastatic neuroblastoma: A report from the HRâ€NBLâ€1/SIOPEN study. Pediatric Blood and Cancer, 2018, 65, e27363.	1.5	53
53	Meta-mining of copy number profiles of high-risk neuroblastoma tumors. Scientific Data, 2018, 5, 180240.	5.3	27
54	Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients. JCI Insight, 2018, 3, .	5.0	28

#	Article	IF	Citations
55	Risk prediction based on post induction bone marrow response and genomic profile: A new way to stratify stage M neuroblastoma patients?. Journal of Clinical Oncology, 2018, 36, 10550-10550.	1.6	0
56	Abstract 2592: Whole-exome sequencing cell free DNA analysis documents new tumor specific alterations at relapse of high-risk pediatric cancers. , 2018, , .		0
57	Kids Enter the MATCH. Journal of the National Cancer Institute, 2017, 109, djw305.	6.3	1
58	Longâ€term results of the transmanubrial osteomuscularâ€sparing approach for pediatric tumors. Pediatric Blood and Cancer, 2017, 64, e26527.	1.5	6
59	Pediatric Patient With Renal Cell Carcinoma Treated by Successive Antiangiogenics Drugs: A Case Report and Review of the Literature. Journal of Pediatric Hematology/Oncology, 2017, 39, e279-e284.	0.6	3
60	Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. Expert Opinion on Drug Discovery, 2017, 12, 1-11.	5.0	28
61	Feasibility and clinical integration of molecular profiling for target identification in pediatric solid tumors. Pediatric Blood and Cancer, 2017, 64, e26365.	1.5	56
62	Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nature Genetics, 2017, 49, 1408-1413.	21.4	331
63	From class waivers to precision medicine in paediatric oncology. Lancet Oncology, The, 2017, 18, e394-e404.	10.7	45
64	Radiogenomics of neuroblastomas: Relationships between imaging phenotypes, tumor genomic profile and survival. PLoS ONE, 2017, 12, e0185190.	2.5	40
65	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	1.6	219
66	Abstract 4952: Whole exome sequencing of circulating tumor DNA highlights spatial and temporal tumor heterogeneity in neuroblastoma. , 2017, , .		1
67	Abstract CT004: European pediatric precision medicine program in recurrent tumors: first results from MAPPYACTS molecular profiling trial towards AcSe-ESMART proof-of-concept study. , 2017, , .		8
68	Is Nephron Sparing Surgery Justified in Wilms Tumor With Beckwithâ€“Wiedemann Syndrome or Isolated Hemihypertrophy?. Pediatric Blood and Cancer, 2016, 63, 1571-1577.	1.5	19
69	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalinâ€Fixed Paraffinâ€Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	1.5	13
70	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma:ÂA study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	2.8	56
71	Oncologic Phenotype of Peripheral Neuroblastic Tumors Associated With PHOX2B Nonâ€Polyalanine Repeat Expansion Mutations. Pediatric Blood and Cancer, 2016, 63, 71-77.	1.5	14
72	Genomic Copy Number Profiling Using Circulating Free Tumor DNA Highlights Heterogeneity in Neuroblastoma. Clinical Cancer Research, 2016, 22, 5564-5573.	7.0	108

#	Article	IF	Citations
73	Neuroblastoma. Nature Reviews Disease Primers, 2016, 2, 16078.	30.5	907
74	A Dilated Cardiomyopathy Revealing a Neuroblastoma: Which Link?. Journal of Pediatric Hematology/Oncology, 2016, 38, e251-e253.	0.6	5
75	Implementation of mechanism of action biology-driven early drug development for children with cancer. European Journal of Cancer, 2016, 62, 124-131.	2.8	58
76	Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSÃ© phase II trial.. Journal of Clinical Oncology, 2016, 34, 11509-11509.	1.6	9
77	Identification of differentALKmutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget, 2016, 7, 87301-87311.	1.8	20
78	Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma. Oncotarget, 2016, 7, 1960-1972.	1.8	26
79	Detection of tumor <scp>ALK</scp> status in neuroblastoma patients using peripheral blood. Cancer Medicine, 2015, 4, 540-550.	2.8	65
80	Minimally invasive surgery of neuroblastic tumors in children: Indications depend on anatomical location and imageâ€defined risk factors. Pediatric Blood and Cancer, 2015, 62, 257-261.	1.5	50
81	Imageâ€defined risk factor assessment of neurogenic tumors after neoadjuvant chemotherapy is useful for predicting intraâ€operative risk factors and the completeness of resection. Pediatric Blood and Cancer, 2015, 62, 1543-1549.	1.5	61
82	Bone Vertebrae Metastases With Spinal Cord Compression. Journal of Pediatric Hematology/Oncology, 2015, 37, e387-e389.	0.6	3
83	Information sur le stockage et lâ€™utilisation des Ã©chantillons biologiques en oncologie pÃ©diatrique. Revue D'Oncologie HÃ©matologie PÃ©diatrique, 2015, 3, 123-124.	0.1	0
84	Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nature Genetics, 2015, 47, 864-871.	21.4	451
85	Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification. British Journal of Cancer, 2015, 112, 290-295.	6.4	39
86	Long-term side effects of radiotherapy for pediatric localized neuroblastoma. Strahlentherapie Und Onkologie, 2015, 191, 604-612.	2.0	32
87	Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis. Clinical Cancer Research, 2015, 21, 4913-4921.	7.0	62
88	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. Journal of Clinical Oncology, 2015, 33, 3008-3017.	1.6	637
89	Revised Risk Estimation and Treatment Stratification of Low- and Intermediate-Risk Neuroblastoma Patients by Integrating Clinical and Molecular Prognostic Markers. Clinical Cancer Research, 2015, 21, 1904-1915.	7.0	80
90	Abstract 2980: Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. , 2015, , .		0

#	Article	IF	Citations
91	Clinical Characteristics and Outcome of Patients with Neuroblastoma Presenting Genomic Amplification of Loci Other than MYCN. PLoS ONE, 2014, 9, e101990.	2.5	17
92	Malformations, genetic abnormalities, and wilms tumor. Pediatric Blood and Cancer, 2014, 61, 140-144.	1.5	57
93	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study. British Journal of Cancer, 2014, 111, 227-233.	6.4	49
94	Emergence of New ALK Mutations at Relapse of Neuroblastoma. Journal of Clinical Oncology, 2014, 32, 2727-2734.	1.6	176
95	SegAnnDB: interactive Web-based genomic segmentation. Bioinformatics, 2014, 30, 1539-1546.	4.1	10
96	Recent insights into the biology of neuroblastoma. International Journal of Cancer, 2014, 135, 2249-2261.	5.1	91
97	A neuroblastoma risk classification model for developing countries: A study from the International Neuroblastoma (NB) Risk Group (INRG) database.. Journal of Clinical Oncology, 2014, 32, 10030-10030.	1.6	1
98	Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma. Oncotarget, 2014, 5, 2688-2702.	1.8	89
99	Emergence of new ALK mutations at relapse of neuroblastoma.. Journal of Clinical Oncology, 2014, 32, 11006-11006.	1.6	0
100	Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney (CCSK): A combined SIOP and AIEOP study.. Journal of Clinical Oncology, 2014, 32, 10041-10041.	1.6	1
101	Characterization of Rearrangements Involving the ALK Gene Reveals a Novel Truncated Form Associated with Tumor Aggressiveness in Neuroblastoma. Cancer Research, 2013, 73, 195-204.	0.9	54
102	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. Pediatric Blood and Cancer, 2013, 60, 332-335.	1.5	3
103	Update on Pediatric Opsoclonus Myoclonus Syndrome. Neuropediatrics, 2013, 44, 324-329.	0.6	51
104	Learning smoothing models of copy number profiles using breakpoint annotations. BMC Bioinformatics, 2013, 14, 164.	2.6	33
105	Breakpoint Features of Genomic Rearrangements in Neuroblastoma with Unbalanced Translocations and Chromothripsis. PLoS ONE, 2013, 8, e72182.	2.5	42
106	Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics, 2012, 28, 423-425.	4.1	847
107	ALK germline mutations in patients with neuroblastoma: a rare and weakly penetrant syndrome. European Journal of Human Genetics, 2012, 20, 291-297.	2.8	38
108	Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British Journal of Cancer, 2012, 107, 1418-1422.	6.4	151

#	Article	IF	Citations
109	Analysis of genomic alterations in neuroblastoma by multiplex ligation-dependent probe amplification and array comparative genomic hybridization: a comparison of results. Cancer Genetics, 2012, 205, 657-664.	0.4	6
110	Riskâ€adapted therapy for infantile myofibromatosis in children. Pediatric Blood and Cancer, 2012, 59, 115-120.	1.5	47
111	Desmoplastic small round cell tumors with EWSâ€WT1 fusion transcript in children and young adults. Pediatric Blood and Cancer, 2012, 58, 891-897.	1.5	45
112	Transcription Factor E3 and Transcription Factor EB Renal Cell Carcinomas: Clinical Features, Biological Behavior and Prognostic Factors. Journal of Urology, 2011, 185, 24-29.	0.4	91
113	Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative) Tj ETQq1 1 0.784314 rgBT /Overlock	6.1	82
114	Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Pediatric Blood and Cancer, 2011, 56, 757-761.	1.5	29
115	Diagnostic and prognostic information obtained on fineâ€needle aspirates of primary neuroblastic tumors. Cancer Cytopathology, 2011, 119, 411-423.	2.4	23
116	A Multilocus Technique for Risk Evaluation of Patients with Neuroblastoma. Clinical Cancer Research, 2011, 17, 792-804.	7.0	39
117	Opsoclonusâ€“myoclonus in children associated or not with neuroblastoma. European Journal of Paediatric Neurology, 2010, 14, 400-409.	1.6	72
118	Molecular pathogenesis of peripheral neuroblastic tumors. Oncogene, 2010, 29, 1566-1579.	5.9	84
119	An integrative genomics screen uncovers ncRNA T-UCR functions in neuroblastoma tumours. Oncogene, 2010, 29, 3583-3592.	5.9	141
120	Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Annals of Oncology, 2010, 21, 1834-1838.	1.2	188
121	Prognostic Impact of Gene Expressionâ€“Based Classification for Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3506-3515.	1.6	129
122	Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. Journal of Medical Genetics, 2010, 47, 859-862.	3.2	57
123	Accumulation of Segmental Alterations Determines Progression in Neuroblastoma. Journal of Clinical Oncology, 2010, 28, 3122-3130.	1.6	142
124	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
125	Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma. Journal of Clinical Oncology, 2009, 27, 1026-1033.	1.6	288
126	WNT/Î²â€catenin pathway activation in Wilms tumors: A unifying mechanism with multiple entries?. Genes Chromosomes and Cancer, 2009, 48, 816-827.	2.8	50

#	Article	IF	Citations
127	Management of Wilms tumors in Drash and Frasier syndromes. Pediatric Blood and Cancer, 2009, 52, 55-59.	1.5	43
128	International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee. British Journal of Cancer, 2009, 100, 1471-1482.	6.4	330
129	Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncology, The, 2009, 10, 663-671.	10.7	176
130	Preoperative Wilms tumor rupture. Cancer, 2008, 113, 202-213.	4.1	35
131	Characterization of amplicons in neuroblastoma: Highâ€resolution mapping using DNA microarrays, relationship with outcome, and identification of overexpressed genes. Genes Chromosomes and Cancer, 2008, 47, 819-834.	2.8	39
132	Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature, 2008, 455, 967-970.	27.8	787
133	High Cyclin E Staining Index in Blastemal, Stromal or Epithelial Cells Is Correlated with Tumor Aggressiveness in Patients with Nephroblastoma. PLoS ONE, 2008, 3, e2216.	2.5	15
134	Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatric Blood and Cancer, 2007, 48, 311-317.	1.5	41
135	Hypertension in Childhood Cancer. Journal of Pediatric Hematology/Oncology, 2006, 28, 659-664.	0.6	50
136	Stepwise occurrence of a complex unbalanced translocation in neuroblastoma leading to insertion of a telomere sequence and late chromosome 17q gain. Oncogene, 2005, 24, 3377-3384.	5.9	36
137	Preferential Occurrence of Chromosome Breakpoints within Early Replicating Regions in Neuroblastoma. Cell Cycle, 2005, 4, 1842-1846.	2.6	33
138	Gene expression profiling of 1p35â€“36 genes in neuroblastoma. Oncogene, 2004, 23, 5912-5922.	5.9	60
139	Variety and complexity of chromosome 17 translocations in neuroblastoma. Genes Chromosomes and Cancer, 2004, 39, 143-150.	2.8	35
140	Germline Mutations of the Pairedâ€“Like Homeobox 2B (PHOX2B) Gene in Neuroblastoma. American Journal of Human Genetics, 2004, 74, 761-764.	6.2	288
141	Combined 24-color karyotyping and comparative genomic hybridization analysis indicates predominant rearrangements of early replicating chromosome regions in neuroblastoma. Cancer Genetics and Cytogenetics, 2003, 141, 32-42.	1.0	53
142	Increased Risk of Systemic Relapses Associated With Bone Marrow Micrometastasis and Circulating Tumor Cells in Localized Ewing Tumor. Journal of Clinical Oncology, 2003, 21, 85-91.	1.6	203
143	CGH analysis of secondary genetic changes in Ewing tumors:. Cancer Genetics and Cytogenetics, 2001, 130, 57-61.	1.0	39
144	Autologous haematopoietic stem cell transplantation for paediatric solid tumours. Best Practice and Research in Clinical Haematology, 1999, 12, 247-259.	1.7	9

#	Article	IF	Citations
145	Clinical relevance of loss of heterozygosity of the short arm of chromosome 1 in neuroblastoma: A single-institution study. , 1996, 69, 73-78.		34
146	Two distinct deleted regions on the short arm of chromosome I in neuroblastoma. Genes Chromosomes and Cancer, 1994, 10, 275-281.	2.8	144